Vaxcyte Shares Acquired by Boothbay Fund Management

Boothbay Fund Management increases stake in biotech company Vaxcyte by 24.7% in Q3

Mar. 16, 2026 at 7:52am

Got story updates? Submit your updates here. ›

Boothbay Fund Management LLC has increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 24.7% during the third quarter, according to a recent SEC filing. The fund now owns 128,731 shares of the company's stock, worth approximately $4.64 million.

Why it matters

Vaxcyte is a clinical-stage biotech company focused on developing a new generation of preventive vaccines targeting serious bacterial diseases. The increase in Boothbay's stake suggests the fund sees growth potential in Vaxcyte's pipeline and technology.

The details

According to the filing, Boothbay Fund Management acquired an additional 25,464 shares of Vaxcyte during the third quarter, bringing its total ownership to approximately 0.10% of the company's outstanding shares. Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

  • Boothbay Fund Management increased its Vaxcyte holdings during the third quarter of 2026.

The players

Boothbay Fund Management LLC

An investment management firm that has increased its stake in Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines for serious bacterial diseases.

Got photos? Submit your photos here. ›

The takeaway

Boothbay Fund Management's increased investment in Vaxcyte suggests the fund sees strong growth potential in the biotech company's pipeline and technology, particularly its lead pneumococcal vaccine candidate VAX-24.